Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of TS, XPO, TDOC and AGN

CEDARHURST, N.Y., Jan. 24, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Tenaris S.A. TS
A class action has commenced on behalf of shareholders in Tenaris S.A. who purchased shares between May 1, 2014 and November 27, 2018. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Tenaris's CEO and Chairman, Paolo Rocca, knew that one of his company's executives paid cash to government officials from 2009 to 2012 to expedite compensation payments for the sale of Sidor; (2) this conduct would lead to Rocca being charged in a graft scheme, and subject Tenaris, its affiliates, and/or executives to heightened governmental scrutiny; and (3) as a result, Tenaris's public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Shareholders may find more information at https://kseclaw.com/securities/tenaris-s-a-loss-form/?wire=3

XPO Logistics, Inc. XPO
A class action has commenced on behalf of shareholders in XPO Logistics, Inc. who purchased shares between February 26, 2014 and December 12, 2018. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) XPO's highly touted aggressive M&A strategy had yielded only minimal returns to the Company; (ii) XPO was utilizing improper accounting practices to mask its true financial condition, including, inter alia, under-reporting of bad debts and aggressive amortization assumptions; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kseclaw.com/securities/xpo-logistics-inc/?wire=3

Teladoc Health, Inc. TDOC
A class action has commenced on behalf of shareholders in Teladoc Health, Inc. who purchased shares between March 3, 2016 and December 5, 2018. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Executive Vice President and Chief Operating Officer Mark Hirschhorn was engaged in an inappropriate sexual relationship with a subordinate; (ii) Hirschhorn and this subordinate engaged in insider trading to provide themselves with undue benefits; (iii) Hirschhorn caused the subordinate to receive promotions for which she was unqualified, thereby negatively impacting the Company's operations; (iv) the Company's enforcement of its own purported employment and trading policies were inadequate to prevent the foregoing conduct; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kseclaw.com/securities/teladoc-health-inc/?wire=3

Allergan plc AGN
A class action has commenced on behalf of shareholders in Allergan plc who purchased shares between May 9, 2017 and December 19, 2018. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: During the Class Period, and unbeknownst to investors, Allergan misled investors regarding various "pharma and device approvals" and concealed the fact that the Company's CE Mark for its textured breast implants and tissue expanders was expiring in Europe.    On December 19, 2018, the Company announced that, following a compulsory recall request from Agence Nationale de Sécurité du Médicament ("ANSM"), the French regulatory authority, the Company had suspended the sale of these products and that it was withdrawing all remaining supplies from European markets. The suspension of sales stemmed directly from the expiration of the company's CE Mark for these products, and the stock price fell drastically following the news.

Shareholders may find more information at https://kseclaw.com/securities/allergan-plc/?wire=3

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.

CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 334
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967